Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Defending champions Arsenal squeezed into the FA Cup final despite a spirited fightback from Reading, who forced extra-time
A detective who led investigations into the Valley Parade fire tells ITV News there is "unequivocal" evidence the disaster was an accident.
Tonight will start off clear in many areas, but cloud will increase from the east overnight, bringing some light and patchy rain.